现代成本分析显示药物治疗是BPH/LUTS极具成本效益的一线方案
该综述综合随机试验、荟萃分析、国际指南及成本效果分析,评估药物治疗作为BPH/LUTS初始管理的成本效益。常见仿制药(如坦索罗辛和非那雄胺)月费用约2-7美元,经济模型一致显示药物治疗相较观察等待或手术具有有利的增量成本效果比。结论支持药物治疗为极具成本效益的一线选择,手术应保留用于药物失败、并发症或患者偏好。
要点
- 仿制药竞争大幅降低BPH/LUTS药物成本,月费用约2-7美元。
- α受体阻滞剂和5α还原酶抑制剂可改善症状并降低进展风险,联合治疗尤著。
- 药物相比观察等待或手术具有利增量成本效果比,手术应留作二线。
核心结论
- 当代临床与经济证据支持药物治疗为BPH/LUTS极具成本效益的一线治疗。
- 手术干预最好保留用于药物失败、并发症或患者偏好。
研究设计与样本
- 综述综合随机试验、荟萃分析、国际指南及已发表成本效果/成本效用分析。
- 比较药物治疗与常见微创及手术BPH干预。
主要发现
- 常见仿制药(如坦索罗辛和非那雄胺)通过折扣项目月费用约2-7美元。
- 临床试验证据显示α受体阻滞剂和5α还原酶抑制剂可显著改善症状并降低进展风险,联合治疗尤著。
- 已发表经济模型一致显示药物治疗相较观察等待或手术具有有利的增量成本效果比。
- 在当前仿制药定价下,药物成本在典型寿命内很少接近程序干预的一次性成本。
临床怎么用
- 可将药物治疗作为BPH/LUTS的一线管理策略。
- 手术干预应保留用于药物治疗失败、出现并发症或患者偏好时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/OBJECTIVES: Generic competition has markedly reduced the cost of medications for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), potentially reshaping the value proposition of first-line therapy. We reviewed contemporary drug pricing and health-economic evidence to evaluate the cost-effectiveness of medical therapy as initial management for BPH/LUTS. SUBJECTS/METHODS: We synthesized evidence from randomized trials, meta-analyses, international guidelines, and published cost-effectiveness/cost-utility analyses comparing pharmacotherapy with common minimally invasive and surgical BPH interventions. RESULTS: Common generic agents (e.g., tamsulosin and finasteride) are available for approximately $2-$7 per month through discount programs. Clinical trial evidence demonstrates meaningful symptom improvement and reduced risk of progression with alpha-blockers and 5-alpha-reductase inhibitors, particularly in combination therapy. Published economic models consistently show favorable incremental cost-effectiveness ratios for medical management versus watchful waiting or surgery; under current generic pricing, medication costs rarely approach the one-time costs of procedural interventions within a typical lifespan. CONCLUSIONS: Contemporary clinical and economic evidence supports medical therapy as a highly cost-effective first-line treatment for BPH/LUTS, with procedural interventions best reserved for medication failure, complications, or patient preference.
引用
- Te AE, Ramaswamy A, Kaplan SA, et al. Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS. Prostate Cancer Prostatic Dis. 2026. PMID: 41723274. doi:10.1038/s41391-026-01089-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。